Sunday, March 01, 2015 8:42:35 PM
• Waterhouse patent in Europe EP1068311 upheld in opposition proceedings
• EPO opposition hearing for Graham EP1624060 patent scheduled for June 2015
Sydney, Australia, March 2, 2015: Benitec Biopharma Limited (ASX: BLT, OTC: BTEBY) is pleased to advise that the European Opposition Division has upheld CSIRO’s platform RNAi patent from the Waterhouse family, EP 1068311, in an amended form. Benitec is the exclusive worldwide licensee of this patent for human therapeutic applications. The opposition hearing was held in The Hague on 7 and 8 January 2015 and was jointly attended by CSIRO, and Benitec and Bayer representatives as exclusive licensees in human therapeutics and plant fields, respectively.
The European Examining Division granted EP 1068311 on 31 March 2011 and the grant was opposed by four parties – BASF SE, Syngenta International AG, Carnegie Institution of Washington/University of Massachusetts and Strawman Limited (subsequently identified as Galapagos NV). The patent was upheld in the opposition hearing with amendments to focus the patent claims to hairpin RNA molecules produced from the genetic constructs of DNA- delivered RNAi (ddRNAi). This patent from the Waterhouse family complements the foundational RNAi patents of the Graham patent family. The Waterhouse patent family has no limitations on the maximum length of the constructs generated by ddRNAi, offering broad protection for the platform technology.
In addition to this, Benitec also announces the hearing date for an opposition hearing for a European patent in the Graham family. EP 1624060 was granted in Europe on 1 September 2011 and has been opposed by a single party, BASF SE. The hearing is scheduled to be held in The Hague on 17 June 2015. This patent is the second filing in a suite of patents filed in Europe for the Graham family. The first European patent, EP 1555317, was revoked in opposition proceedings in May 2014. CSIRO and Benitec appealed this decision of revocation on 21 November 2014; see ASX announcement of 25 November 2014, entitled “Benitec files appeal to Graham patent in Europe”.
Ms Sakura Holloway, IP Counsel at Benitec, commented, “The key difference between the two EP Graham patents is in the length of the expressed RNA. The arguments that were filed in the Statement of Appeal for EP 1555317 were very carefully considered and are also relevant to the second Graham patent. We expect positive outcomes in both cases.”
Recent BNTC News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/29/2024 08:28:27 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/19/2024 08:59:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 09:18:32 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2024 02:22:02 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/29/2024 08:32:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:05:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 12:01:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:13:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:12:19 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 02/26/2024 02:06:56 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/23/2024 09:09:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:15:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 01:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 12:31:00 PM
- Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/17/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:03:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:00:49 PM
- Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/20/2023 08:31:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/20/2023 10:04:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:29:59 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM